Frank Rauzi, MD
Family Medicine · Littleton, CONPI 1881688620
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 91 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 25 manufacturers reported payments, led by AbbVie at 35.3% of the total.
Across 91 payments — averaging $18.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$607
- Pfizer$190
- Johnson & Johnson$120
- Otsuka America Pharmaceutical, Inc.$81
- Biohaven Pharmaceutical Holding Company Ltd.$67
- Abbott$66
- plus $587 from 19 others
Across 69 payments — averaging $2416.18 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$128K
- Kowa Research Institute, Inc.$31K
- Sandoz$5K
- Takeda Pharmaceuticals U.S.A., Inc.$2K
- Sanofi-aventis U.S. LLC$1K
What the payments were for
- Food & beverage$1,718100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 32 | $607 |
| Pfizer | 9 | $190 |
| Johnson & Johnson | 8 | $120 |
| Otsuka America Pharmaceutical, Inc. | 4 | $81 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $67 |
| Abbott | 3 | $66 |
| Boston Scientific | 3 | $59 |
| AstraZeneca | 3 | $54 |
| Kowa Pharmaceuticals America, Inc. | 2 | $52 |
| Idorsia Pharmaceuticals US Inc | 3 | $49 |
| Amgen | 2 | $43 |
| Lilly USA, LLC | 3 | $42 |
| GSK | 3 | $40 |
| Scilex Pharmaceuticals Inc. | 2 | $38 |
| Novartis | 1 | $28 |
| Harmony Biosciences LLC | 1 | $28 |
| Astellas Pharma US Inc | 1 | $28 |
| Boehringer Ingelheim | 1 | $25 |
| Nestle Healthcare Nutrition Inc. | 1 | $18 |
| Merck | 1 | $16 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| Adlon Therapeutics L.p. | 1 | $14 |
| Novo Nordisk | 1 | $13 |
| Amarin Pharma, Inc. | 1 | $13 |
| Eisai Inc. | 1 | $11 |
How this compares
$1,718 in reported general payments places this provider in the 85th percentile of 2,079 family medicine providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 41 | $44,497 |
| XareltoRivaroxaban | 24 | $22,375 |
| JanuviaSitagliptin Phosphate | 12 | $18,483 |
| MyrbetriqMirabegron | 18 | $16,107 |
| SynthroidLevothyroxine Sodium | 33 | $2,813 |
| Levothyroxine Sodium | 231 | $2,383 |
| Omeprazole | 66 | $1,749 |
| Gabapentin | 60 | $1,588 |
| Atorvastatin Calcium | 205 | $1,535 |
| Lisinopril | 185 | $1,395 |
| Simvastatin | 159 | $1,153 |
| Losartan Potassium | 107 | $968 |
| Tamsulosin Hcl | 78 | $852 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 42 | $793 |
| Amlodipine Besylate | 124 | $756 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $190 | $44,49741 claims |
| Johnson & JohnsonXarelto | $120 | $22,37524 claims |
| MerckJanuvia | $16 | $18,48312 claims |
| Astellas Pharma US IncMyrbetriq | $28 | $16,10718 claims |
| AbbVieSynthroid | $607 | $2,81333 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,079 family medicine providers in Colorado.
Other family medicine in Littleton
- Robert SimsLittleton$12K
- Tamara WilsonLittleton$9K
- Ethan LazarusDenver$688K
- Michael de NardisLarkspur$335K
- Matthew YoungColorado Springs$270K
- Mark DeutchmanDenver$258K
- Kari UusinarkausWoodland Park$254K
- Michael MeekerUsaf Academy$174K
- Carolynn Francavilla BrownLakewood$174K
- Lawrence AndrewsColorado Springs$102K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.